These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
AKT1_drugdiscovery.pdf (3.37 MB)

Discovery of New AKT1 Inhibitors by Combination of In silico Structure Based Virtual Screening Approaches and Biological Evaluations

submitted on 16.01.2019, 00:54 and posted on 16.01.2019, 17:22 by Filip Fratev, Denisse A. Gutierrez, Renato J. Aguilera, suman sirimulla
AKT1 is emerging as a useful target for treating cancer. Herein, we discovered a new set of ligands that inhibit the AKT1, as shown by in vitro binding and cell line studies, using a newly designed virtual screening protocol that combines structure-based pharmacophore and docking screens. Taking together with the biological data, the combination of structure based pharamcophore and docking methods demonstrated reasonable success rate in identifying new inhibitors (60-70%) proving the success of aforementioned approach. A detail analysis of the ligand-protein interactions was performed explaining observed activities.


University of Texas at El Paso School of Pharmacy


Email Address of Submitting Author


The University of Texas at El Paso



ORCID For Submitting Author


Declaration of Conflict of Interest

The authors declare no conflict of interest